SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano, based in the United States, brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. Her appointment comes as the company advances its global expansion strategy, including the pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as CFO of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn and strengthen the balance sheet. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising over $100 million through public and private financings. Her expertise in SEC reporting, investor relations, and strategic transactions is expected to be instrumental as SS Innovations scales its operations.
The SSi Mantra surgical robotic system is designed to make robotic surgery more affordable and accessible globally. SS Innovations, an American company headquartered in India, also offers the SSi Mudra suite of surgical instruments for various procedures, including cardiac surgery. With Romano's leadership, the company aims to enhance its financial operations and accelerate its regulatory and commercial milestones.
For the full press release, visit https://ibn.fm/pAqlP.
About SS Innovations: The company develops innovative surgical robotic technologies with a vision to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and SSi Mudra instruments, which support various surgical robotic procedures.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements: Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause actual results to differ materially. Undue reliance should not be placed on these statements.
